Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Effectiveness of Povidone-Iodine for Nasal Decolonization in Patients with MRSA

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effectiveness of a treatment for patients with (Methicillin-resistant Staphylococcus aureus), a type of bacterial infection that is resistant to many antibiotics. The treatment being tested is a nasal gel containing , a substance known for its ability to kill bacteria. The purpose of the study is to evaluate how well this nasal gel can remove MRSA from the nose of patients.

Participants in the study will use a nasal gel as part of a complete decolonization kit. The study will observe the rate at which MRSA is cleared from the nose six hours after applying the gel. The study will also assess how acceptable the treatment is to patients and healthcare workers through a questionnaire. Additionally, the study will monitor any side effects reported by patients and check the MRSA status again 24 hours after using the kit.

The trial aims to provide valuable information on the effectiveness of the nasal gel in reducing MRSA in patients. This could potentially lead to better treatment options for those affected by this resistant bacterial infection. The study will be conducted over a period, with results expected to help understand the characteristics of patients who remain MRSA positive after using the gel.

The research process

The trial runs in 8 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, ensure that all eligibility criteria are met. This includes being over 18 years old, having a hospital stay longer than 4 days, and being informed about the study. Written consent is required.

  2. Step 2

    Initial screening

    Undergo a nasal screening to confirm MRSA positivity. This is a necessary step to participate in the trial.

  3. Step 3

    Application of nasal gel

    Apply the povidone iodine gel to the nasal area. This is a topical treatment aimed at reducing MRSA presence. Follow the instructions provided for correct application.

  4. Step 4

    Waiting period

    Wait for 6 hours after the application of the nasal gel. This period is crucial for assessing the effectiveness of the treatment.

  5. Step 5

    First follow-up screening

    Undergo a nasal screening 6 hours after the application to evaluate the decolonization rate of MRSA.

  6. Step 6

    Self-questionnaire

    Complete a self-questionnaire to provide feedback on the acceptability of the nasal decolonization kit. This helps in understanding the user experience.

  7. Step 7

    Second follow-up screening

    Undergo another nasal screening 24 hours after the initial application to further assess the decolonization rate.

  8. Step 8

    Reporting adverse events

    Report any adverse events experienced during the trial. This information is important for evaluating the safety of the treatment.

Who can join the trial?

6 criteria

  • Patients who have been readmitted to the hospital and are already positive for MRSA (a type of bacteria that is resistant to many antibiotics) through a nasal screening test.
  • Patients who have been in the hospital for more than 4 days.
  • Patients who are older than 18 years.
  • Patients who have been informed about the study and understand it.
  • Patients who agree to participate and provide their written consent.
  • Patients who are part of the French social security system or are beneficiaries of it.

Who cannot join the trial?

4 criteria

  • Patients who are not diagnosed with MRSA (Methicillin-resistant Staphylococcus aureus) cannot participate.
  • Patients who are younger than 3 years old or older than 4 years old cannot participate.
  • Patients who are not part of the specified clinical trial group cannot participate.
  • Patients who are not considered part of a vulnerable population cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Povidone Iodine is a type of antiseptic that is used to kill bacteria and other germs. In this clinical trial, it is applied as a gel inside the nose to help remove a specific type of bacteria called MRSA. MRSA can cause infections, and the goal of using this gel is to reduce or eliminate the bacteria from the nasal area. The trial aims to see how effective this treatment is in getting rid of MRSA within a few hours after application.

What is already known about the treatment

Povidone Iodine (PVP-I) Gel – This medication is applied topically as a gel inside the nose to help remove MRSA bacteria. It is currently being studied in clinical trials to see how well it works for this purpose. The main use of this gel is to help clear MRSA, a type of bacteria that can cause infections, from the nasal passages. Povidone iodine works by releasing iodine, which kills bacteria by disrupting their proteins and other essential components. It is classified as an antiseptic, which means it is used to prevent infection by killing or stopping the growth of harmful microorganisms.

Investigated diseases

Methicillin-resistant Staphylococcus aureus (MRSA) infection – This infection is caused by a type of staph bacteria that has become resistant to many antibiotics used to treat ordinary staph infections. MRSA can cause a variety of problems ranging from skin infections to more severe infections such as pneumonia or bloodstream infections. It often begins as a small red bump that resembles a pimple, boil, or spider bite. These can quickly turn into deep, painful abscesses that require surgical draining. Sometimes the bacteria remain confined to the skin, but they can also burrow deeper into the body, causing potentially more serious infections. The bacteria are typically spread by direct contact with an infected wound or by sharing personal items that have touched infected skin.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2022-500642-25-00Protocol codeRC21_0556Estimated enrolment50 patientsSponsorCentre Hospitalier Universitaire De Nantes

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).